M&A
confidence high
sentiment positive
materiality 0.70
DMII proposes $600M combination with Alpha AI Biotech paid in 60M shares at $10.00
Drugs Made In America Acquisition II Corp.
- Preliminary, nonbinding proposal values Alpha AI Biotech Group at $600 million pre-money, payable in 60,000,000 ordinary shares at $10.00 per share.
- Up to 30,000,000 additional earn-out shares in two equal tranches tied to share-price thresholds of $12.50 and $15.00 during 24 months after closing.
- Board approved a 30-day limited standstill expiring on or about December 3, 2026; no definitive agreement, due diligence and audited financials still pending.
- Investor Tal Alpha funded $250,000 on November 6, 2026; notes consolidated into a $700,000 convertible note maturing June 30, 2027, convertible at a 35% discount; $700,000 remains available.
- Alon Izidor Tal, CEO of the Investor, is also an Alpha director and acknowledged the proposal on Alpha's behalf.
Featured in Daily 8-K Digest
Selected #4 for 2026-11-18.
Read digest